Background. Enterococcal peritonitis is a serious complication of peritoneal dialysis (PD), although reports of this condition in the literature are exceedingly limited. Methods. The frequency, predictors, treatment and clinical outcomes of enterococcal peritonitis were investigated in all 4675 patients receiving PD in Australia between 1 October 2003 and 31 December 2006. Results. One hundred and sixteen episodes of enterococcal peritonitis occurred in 103 individuals. Enterococcal peritonitis tended to be associated with older age, Maori and Pacific Islander racial origin, renovascular disease and coronary artery disease. Polymicrobial peritonitis, defined as recovery of two or more organisms from dialysate effluent, was significantly more common when an Enterococcus species was isolated than when it was not (45% vs 5%, respectively, P < 0.001, odds ratio 13.4, 95% CI 9.45-19.0). Although international guidelines recommend intraperitoneal ampicillin therapy, only 8% of patients with pure enterococcal peritonitis were treated with this agent, whilst the majority (78%) received vancomycin monotherapy. Overall, 59 (51%) patients with enterococcal peritonitis were successfully treated with antibiotics without experiencing relapse, catheter removal or death. The sole independent predictor of adverse clinical outcomes was recovery of additional (non-Enterococcus) organisms. Polymicrobial enterococcal peritonitis was associated with very high rates of hospitalization (83%), catheter removal (52%), permanent haemodialysis transfer (50%) and death (5.8%). In contrast, clinical outcomes were broadly comparable for pure enterococcal and nonenterococcal peritonitis (hospitalization 75% vs 69%, respectively; catheter removal 25% vs 21%; permanent haemodialysis transfer 17% vs 17%; death 1.6% vs 2.2%) although worse than non-enterococcal Gram-positive peritonitis (63%, 12%, 3% and 0.6%, respectively). Removal of the PD catheter within 1 week of enterococcal peritonitis onset was associated with a lower probability of permanent haemodialysis transfer than later removal (74% vs 100%, P = 0.03). Conclusions. Enterococcal peritonitis is associated with an increased risk of catheter removal, permanent haemodialysis transfer and death, particularly when other organisms are isolated in the same episode.
Introduction
Enterococci are facultatively anaerobic, Gram-positive cocci that have been identified as important pathogens for more than a century [1, 2] . The two most common enterococci, Enterococcus faecalis and Enterococcus faecium, are commensals of the human intestine, which play a prominent role in nosocomial infections and exhibit a propensity to develop antimicrobial resistance. In 1984, DNA hybridization techniques demonstrated the separateness of enterococci from streptococci, and the genus Enterococcus was formally defined [3] .
Enterococcal peritonitis accounts for between 2% and 4% of peritoneal dialysis (PD)-associated peritonitis [4] [5] [6] [7] and has variously been reported to have antimicrobial response rates that are similar to [4] [5] [6] , or worse than [7] , other types of Gram-positive peritonitis. The 2005 update of the International Society of PD (ISPD) Guidelines for Management of PD-Related Infections recommends that enterococcal peritonitis tends to be severe and is best treated with intraperitoneal (IP) ampicillin with or without an aminoglycoside for synergy [8] . However, these recommendations are based on limited observations from older, small clinical studies involving single centres (often where PD expertise is concentrated) [6, 7] . Moreover, there has not previously been a comprehensive examina-tion of different therapeutic approaches to enterococcal peritonitis.
The aim of the current study was to examine the frequency, predictors, treatment and clinical outcomes of enterococcal peritonitis in all Australian PD patients.
Materials and methods

Study population
The study included all Australian adult patients from the Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry who were receiving PD between 1 October 2003 (when detailed peritonitis data started to be collected) and 31 December 2006. The data collected included demographic data, cause of primary renal disease, comorbidities at the start of dialysis (coronary artery disease, peripheral vascular disease, cerebrovascular disease, chronic lung disease, diabetes, hypertension and smoking status), body mass index (BMI), late referral (defined as commencement of dialysis within 3 months of referral to a nephrologist), microbiology of peritonitis episodes (up to three organisms for polymicrobial episodes) and the initial and subsequent antibiotic treatment regimens. Enterococcal peritonitis was defined as clinical features of peritonitis (abdominal pain or cloudy dialysate), dialysate leukocytosis (white blood cell count >100 /μL with >50% neutrophils) and isolation of Enterococcus species from dialysate culture. In cases of polymicrobial peritonitis, enterococcal peritonitis was recorded if an Enterococcus species was at least one of the isolated organisms. Information about the specific Enterococcus species isolated (E. faecalis, E. faecium or other) was not recorded by the ANZDATA Registry. Antibiotic durations were calculated as the time period between antibiotic commencement and cessation. Centre size was categorized according to quartiles of the numbers of patients cared for by individual units over the duration of the study: small (<11 patients), small-medium (11-38 patients), medium-large (39-98 patients) and large (>99 patients).
The outcomes examined were peritonitis relapse, repeat peritonitis, peritonitis-associated hospitalization, catheter removal, temporary or permanent transfer to haemodialysis and patient death. Peritonitis relapse was defined as an episode of peritonitis occurring within 4 weeks of the last antibiotic dose (or within 5 weeks if vancomycin is used intermittently) for peritonitis due to the same organism. Repeat peritonitis was defined as an episode of peritonitis occurring more than 4 weeks after the last antibiotic dose (or more than 5 weeks if vancomycin is used intermittently) for peritonitis due to the same organism. Peritonitis-related death was recorded if the patient's death was directly attributable to peritonitis in the clinical opinion of the treating nephrologist.
Statistical analysis
Results were expressed as frequencies and percentages for categorical variables, mean ± standard deviation for continuous variables and median and interquartile range for non-parametric data. Differences between two groups of patients were analysed by chi-square test for categorical data, unpaired t-test for continuous parametric data and Mann-Whitney test for continuous non-parametric data. Comparisons of outcomes between enterococcal, polymicrobial enterococcal and non-enterococcal peritonitis were made by the chi-square test for categorical data and the Kruskal-Wallis test for continuous, non-parametric data. The independent predictors of culture-negative peritonitis were determined by binary logistic regression and multivariate Poisson regression using backward stepwise elimination. For Poisson analyses, the correlation between observations (intraclass correlation) was taken into account by utilizing a multi-level modelling technique: the hierarchical model took into account clustering based on state of residence, treating unit and individual patient (as patients could have more than one event). Predictors of peritonitis outcomes were determined by multivariate logistic regression using stepwise backward elimination. Data were analysed using the software packages SPSS for Windows release 16.0 (SPSS Inc., North Sydney, Australia) and Stata/SE 9.2 (College Station, TX). P values less than 0.05 were considered statistically significant.
Results
Population characteristics
A total of 4675 patients received peritoneal dialysis in Australia during the study period (1 October 2003 to 31 December 2006). They were followed for 6002 patientyears. In this group, 3594 episodes of peritonitis occurred in 1984 (42%) patients, and 116 episodes of enterococcal peritonitis occurred in 103 individuals. Enterococcus species accounted for 3% of all peritonitis episodes in 2% of all patients. The rates of all peritonitis and enterococcal peritonitis were 0.60 and 0.02 episodes per patient-year of treatment, respectively.
Polymicrobial peritonitis, defined as recovery of two or more organisms from dialysate effluent, was significantly more common with enterococcal than non-enterococcal peritonitis (45% vs 5%, respectively, P < 0.001, odds ratio 13.4, 95% CI 9.45-19.0). Second and third organisms were isolated in 52 (45%) and 16 (14%) episodes of enterococcal peritonitis, respectively. The additional organisms recovered in the polymicrobial cases of enterococcal peritonitis included coagulase-negative staphylococci (n = 9), Staphylococcus aureus (n = 3), streptococci (n = 2), other Grampositive organisms (n = 2), Pseudomonas species (n = 4), Acinetobacter species (n = 1), E. coli (n = 10), Klebsiella (n = 8), Enterobacter (n = 8), Serratia (n = 2), Citrobacter (n = 1), other Gram-negative organisms (n = 5), anaerobic bacteria (n = 1), fungi (n = 8) and other organisms (n = 4).
Predictors of enterococcal peritonitis
The characteristics of patients who did and did not experience enterococcal peritonitis are shown in Table 1 . On univariate analysis, patients who experienced enterococcal peritonitis during the study period were more likely to be older and have coronary artery disease than those individuals who did not experience enterococcal peritonitis. On multivariate analysis of all peritonitis episodes using a multi-level hierarchical Poisson regression model, enterococcal peritonitis tended to be independently predicted by increasing age [youngest tertile reference; middle tertile adjusted incident rate ratio (IRR) 1.41, 95% CI 0.72-2.79; oldest tertile 1.96, 95% CI 0.96-4.00], Maori and Pacific Islander racial origin (IRR 2.86, 95% CI 0.91-9.02 vs Caucasians) and the presence of renovascular disease (IRR 2.14, 95% CI 0.93-4.99) and coronary artery disease (IRR 1.63, 95% CI 0.97-2.73), although none of these covariates achieved statistical significance. The development of enterococcal peritonitis was not associated with gender, BMI, kidney function at dialysis commencement, late referral, smoking status, chronic lung disease, peripheral vascular disease, cerebrovascular disease, diabetes mellitus or centre size.
Treatment of enterococcal peritonitis
Approximately one-half of patients with PD-associated enterococcal peritonitis were initially treated with intraperitoneal vancomycin in combination with gentamicin, whilst Enterococcal peritonitis 1273
one-third were empirically treated with intraperitoneal cephazolin in combination with either gentamicin or a thirdgeneration cephalosporin ( Table 2 ). The initial antibiotic regimen was changed in 82 (71%) enterococcal peritonitis episodes after a median period of 3 days and was significantly more common if other organisms were isolated in addition to Enterococcus species (85% vs 59%, P = 0.006). In the 64 (55%) episodes where Enterococcus alone was isolated, the most common change was cessation of gentamicin and cephalosporin therapy and conver- 
Results represent number of episodes treated with antibiotic (% of total treated with first-, second-or third-line regimen). Note that values within each column add to more than 100% because of the use of combination antimicrobial regimens. sion to vancomycin monotherapy (78% of episodes). A small proportion (11%) of patients were treated with broad-spectrum penicillins (ampicillin or amoxycillin ± clavulanate). Where other organisms were isolated in addition to Enterococcus species, the most common antibiotic prescription was vancomycin and gentamicin. Metronidazole was added as adjunctive therapy in 25% of cases, whilst ciprofloxacin was added in 17% of cases. Overall, the median total antibiotic course durations for enterococcal peritonitis with or without other organisms were 12 and 15.5 days, respectively. In terms of adjunctive therapy, Tenckhoff catheter instillation with either urokinase or streptokinase was performed in two (1.7%) cases of enterococcal peritonitis compared with 28 (0.8%) cases of non-enterococcal peritonitis (P = 0.3). Heparin was administered to dialysate in 24 (21%) episodes of enterococcal peritonitis and 716 (21%) episodes of non-enterococcal peritonitis (P = 1.0). Antifungal chemoprophylaxis (principally oral nystatin) was co-prescribed in five (4%) cases of enterococcal peritonitis and 255 (7%) cases of non-enterococcal peritonitis (P = 0.2).
Outcomes of enterococcal peritonitis
Of the 103 individuals who experienced enterococcal peritonitis during the study period, 10 (10%) experienced repeat peritonitis, 43 (42%) underwent catheter removal and four (4%) patients died (Table 3) . Overall, 59 (51%) patients with enterococcal peritonitis were successfully treated with antibiotics without experiencing relapse, catheter removal or death. Cure with antibiotics alone tended to be more likely with single-organism enterococcal peritonitis than with polymicrobial enterococcal peritonitis (59% vs 40%), although the difference was not statistically significant (P = 0.065). When single-organism infections were considered, enterococcal infections were associated with comparable risks of hospitalization, catheter removal, temporary haemodialysis and permanent haemodialysis to those of S. aureus infections (Table 4 ). The duration of hospitalization was significantly shorter for enterococcal peritonitis than for S. aureus peritonitis. Outcomes for polymicrobial enterococcal peritonitis tended to be better for pure Gram-positive infections than if Gram-negative organisms and/or fungi were also isolated, although the numbers were too small to be able to demonstrate statistical significance (Table 5) . Compared with polymicrobial peritonitis episodes in which enterococci were not isolated, polymicrobial enterococcal peritonitis episodes tended to be associated with lower cure rates with antibiotics alone (40% vs 53%, P = 0.08), higher catheter removal rates (52% vs 42%, P = 0.17) and higher rates of permanent haemodialysis transfer (52% vs 37%, P = 0.06). No differences were observed between the two groups with respect to rates of hospitalization (83% vs 83%, P = 1.0) or death (5.8% vs 3.6%, P = 0.5).
With respect to repeat peritonitis, 93 (90%) patients experienced one enterococcal peritonitis episode, eight (8%) experienced two episodes, one (1%) experienced three episodes and one (1%) experienced four episodes. The median [IQR] time period between repeat enterococcal peritonitis Relapse occurred in 17 (15%) episodes and was significantly more frequent with single-organism than with polymicrobial enterococcal peritonitis episodes (22% vs 6%, P = 0.03; Table 3 ). Using multivariate binary logistic regression, the principal independent predictor of relapse was the occurrence of pure enterococcal peritonitis [odds ratio (OR) 0.22, 95% CI 0.06-0.82] as opposed to polymicrobial enterococcal peritonitis. This finding may represent competing risks since the catheter removal rate was significantly higher for polymicrobial enterococcal peritonitis (52% vs 25%, P = 0.005). Recovery of other organisms in addition to Enterococcus was a significant, independent predictor of both catheter removal (OR 3.61, 95% CI 1.41-9.29) and permanent haemodialysis transfer (OR 5.11, 95% CI 1.81-14.4). When polymicrobial cases of enterococcal peritonitis were excluded, the outcomes of enterococcal peritonitis were not appreciably different from those of non-enterococcal peritonitis (Table 3) .
Effect of timing of catheter removal in enterococcal peritonitis
Tenckhoff catheter removal occurred in 43 (37%) of the 116 episodes of enterococcal peritonitis after a median period of 6 days. When outcomes were compared between early (within 1 week) and late (after 1 week) catheter removal, the probability of permanent haemodialysis transfer was significantly lower in the former group (74% vs 100%, P = 0.03). There was no significant difference observed in the occurrence of death (7% vs 0%, P = 0.3), although numbers were small.
Discussion
The present study represents the only examination to date of the frequency, predictors, treatment and clinical outcomes of PD-associated enterococcal peritonitis. The key findings were that enterococcal peritonitis tended to be associated with older age, vascular disease and Maori and Pacific Is- lander racial origin; other pathogenic organisms were isolated in addition to Enterococcus species in approximately half of all cases of enterococcal peritonitis; and that the recovery of other organisms was the main determinant of clinical outcomes. Pure enterococcal peritonitis had broadly comparable outcomes to those of non-enterococcal peritonitis and S. aureus peritonitis. However, polymicrobial enterococcal peritonitis was associated with very high rates of catheter removal (52%), permanent haemodialysis transfer (52%) and death (6%). These results are generally in keeping with those of a retrospective review of 58 episodes of streptococcal peritonitis (including 19 cases of E. faecalis peritonitis) in 38 patients at a single centre in Spain between 1980 and 1995 [7] . Four (21%) of the 19 cases of enterococcal peritonitis were associated with isolation of other micro-organisms from dialysate effluent. Compared with streptococcal infection, enterococcal peritonitis was associated with older patient age (62.8 vs 54 years, P < 0.05), poorer early response to empiric antibiotics (40% vs 81%, P < 0.05) and a tendency to poorer response to IP ampicillin (73% vs 96%, P < 0.1). Rates of relapsed (7% vs 0%, P = NS) and repeat peritonitis (13% vs 7%, P = NS) also tended to be higher. In contrast to our study, however, Munoz de Bustillo et al. [7] observed a higher incidence of streptococcal/enterococcal peritonitis in female patients. The apparent disparity in findings may be related to the inclusion of streptococcal infections in the earlier analysis, since streptococcal colonization of the female genital tract is well-described [1] .
In the Network 9 study of single-organism peritonitis in 1991, Bunke and coworkers [5] reported 27 cases of enterococcal peritonitis, accounting for 4.1% of all cases of single-organism bacterial peritonitis. Compared with all other forms of Gram-positive peritonitis, enterococcal peritonitis tended to be associated with increased risks of both hospitalization (41% vs 24%, P = 0.057) and death (7.4% vs 2.2%, P = 0.087), although the differences did not quite achieve statistical significance.
Krishnan et al. [4] also reported on the outcomes of 14 cases of enterococcal peritonitis, accounting for 3.5% of peritonitis episodes overall. Thirteen (93%) cases were successfully treated with antibiotics alone and remained on PD, which was slightly better than for Gram-positive peritonitis episodes overall (87%). Similarly, Kim et al. [6] described favourable outcomes in 13 enterococcal peritonitis episodes, with only one catheter removal (8%) and one death (8%). However, the numbers of cases in both of these studies was too small to draw definitive conclusions.
An important finding of the present study was that enterococcal peritonitis is associated with the isolation of additional organisms (mostly Gram-negative) in approximately 50% of all cases. Moreover, isolation of additional organisms is a strong, independent predictor of poorer outcomes, particularly catheter removal and permanent haemodialysis transfer. This was particularly true when the additional organisms were Gram-negative or fungal. Such polymicrobial enterococcal infections involving Gram-negative organisms are likely to represent bacterial translocation from the intestine. This suggests the possibility of underlying bowel pathology as a contributor to poor PD outcomes, although this was unable to be confirmed as the ANZDATA Peritonitis Registry does not collect this specific information.
Antibiotic treatment protocols are rarely reported in series incorporating enterococcal peritonitis. This is usually because such protocols vary or are inconsistently applied over a large number of cases. The 2005 update of the ISPD Guidelines for Management of PD-related Infections recommends that enterococcal peritonitis is best treated with IP ampicillin with or without an aminoglycoside for synergy [6] . However, these recommendations are based on the reported outcomes with ampicillin for streptococcal and enterococcal peritonitis in a single retrospective study [7] . In the present study, similar outcomes were achieved despite the fact that the predominant antibiotic used was vancomycin and only 8% of patients were ultimately treated with ampicillin. Although it is desirable to minimize the use of vancomycin to curtail the possible development of vancomycin-resistant enterococci [9] , the prescription of vancomycin following identification of enterococci may have been due to the greater convenience of intermittent dosing with this agent as opposed to more frequent dosing with IP ampicillin. The average length of antibiotic treatment of enterococcal peritonitis in Australia was approximately 2 weeks, which was appreciably less than the minimum recommended period of 3 weeks [7] . However, it should be noted that the duration of antibiotic course was calculated as the time period between the first and last dose of antibiotic. Given that the last dose of vancomycin would be expected to have a post-dose effect for up to 5-7 days, most patients with enterococcal peritonitis were likely to have effectively received close to 3 weeks of antimicrobial therapy. The timing of catheter removal in cases of refractory enterococcal peritonitis was also found to be important in the present study given that 25% of patients were able to return to PD if their catheters were removed within 1 week, as opposed to 0% if catheters were removed after this. This supports the ISPD recommendation for timely removal within 5 days if enterococcal peritonitis is refractory to appropriate antimicrobial therapy.
Since the ANZDATA Registry does not collect information about antimicrobial susceptibilities, it is not known whether any of the enterococcal peritonitis episodes reported in this study were due to vancomycin-resistant enterococci (VRE). The ISPD Guidelines recommends ampicillin for VRE peritonitis if the organism is ampicillin susceptible. Alternatively, linezolid or quinupristin/dalfopristin should be used to treat VRE peritonitis, although quinupristin/dalfopristin is not active against E. faecalis isolates. No patients in the present study received linezolid or quinupristin/dalfopristin. Previous case reports have described successful treatment with intravenous linezolid (and removal of the catheter) in one case [10] and three cases of VRE peritonitis treated with quinupristin/dalfopristin [11] . One of these three cases required catheter removal, but all continued PD. The largest series of VRE peritonitis was reported from Connecticut [12] . Nine patients experienced peritonitis over an observation period of 2.5 years. All had been exposed to vancomycin in the Enterococcal peritonitis 1277 6 months prior to VRE infection. Management was with a variety of antibiotics, including the administration of IP ampicillin in two cases. Of these, one required Tenckhoff reinsertion, and the other converted to haemodialysis. The strengths of this study included its very large sample size and inclusiveness. We included all patients receiving PD in Australia during the study period, such that a variety of centres were included with varying approaches to the treatment of peritonitis. This greatly enhanced the external validity of our findings. These strengths should be balanced against the study's limitations, which included limited depth of data collection. ANZDATA does not collect important information, such as the presence of concomitant exit site and tunnel infections, patient compliance, individual unit management protocols (including the use of prophylactic mupirocin), laboratory values (such as C-reactive protein and dialysate white cell counts), severity of comorbidities, antibiotic dosages or routes of antibiotic administration, antimicrobial susceptibilities of recovered organisms or speciation of Enterococcus isolates. Even though we adjusted for a large number of patient characteristics, the possibility of residual confounding could not be excluded. In common with other registry, ANZDATA is a voluntary and there is no external audit of data accuracy, including the diagnosis of peritonitis. Consequently, the possibility of coding/ classification bias cannot be excluded. Furthermore, the reasons underpinning antibiotic choices, changes and treatment durations were not captured by ANZDATA, making it difficult to draw firm conclusions about the relationship between prescribed antibiotics and outcomes. For example, in the absence of information about laboratory sensitivities or early response to treatment, it is difficult to determine whether antibiotic changes were appropriate or otherwise and whether they represented a step-down or step-up due to satisfactory or unsatisfactory progress, respectively.
In conclusion, enterococcal peritonitis is a serious complication of PD, which is significantly more common in older patients and is associated with the isolation of other organisms in approximately 50% of cases. The outcomes of enterococcal peritonitis are comparable to those of S. aureus peritonitis, such that only 59% will be successfully treated with antibiotics alone. The cure rate falls to 40% when additional organisms are isolated. Timely removal of the PD catheter within 1 week of the onset of refractory enterococcal peritonitis is associated with a significant reduction in the risk of permanent haemodialysis transfer.
